# Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD

> **NCT00041483** · PHASE3 · COMPLETED · sponsor: **Alcon Research** · enrollment: 530 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Anecortave Acetate 15 mg sterile suspension
- **OTHER:** Photodynamic Therapy (PDT)

## Key facts

- **NCT ID:** NCT00041483
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** 530 (ACTUAL)
- **Last updated:** 2014-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00041483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00041483, "Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00041483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*